Found 32 matching trials
PTC-guided Neoadjuvant Therapy For Muscle-invasive Bladder Cancer PHASE2 This study evaluates Patient-derived Tumor-like Cell Clusters (PTC)-guided ...
Show More Location
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Learn More & Join Trial
To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer PHASE2 The purpose of this study is to evaluate the efficacy and safety of Disitam...
Show More Learn More & Join Trial
RC48 Combined With Tislelizumab for Bladder Sparing Treatment in NMIBC With BCG Treatment Failure and HER2 Expression PHASE2 This is a prospective, open, single-center clinical study of anti-HER2-ADC ...
Show More Location
Ethics Committee of Shanghai Renji Hospital
Learn More & Join Trial
Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial PHASE3 The goal of this multicentre, randomized, double-blind controlled, phase II...
Show More Location
Sun Yat-sen Memorial Hospital,Sun Yat-sen University
Learn More & Join Trial
Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing PHASE2 Patients with salivary gland carcinoma were divided into groups according t...
Show More Learn More & Join Trial
RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II Study PHASE2 This multicenter, Phase II study (RADIANT-BC01) evaluates the efficacy and ...
Show More Location
The First Affiliated Hospital with Nanjing Medical University
Learn More & Join Trial
Biomarker-Enriched Kidney-Preserving Strategy With Disitamab Vedotin Plus Tislelizumab in HER2-Positive High-Risk Upper Tract Urothelial Carcinoma PHASE2 This is a prospective, multicentre, single-arm phase II study evaluating a ...
Show More Location
Ethics Committee of Shanghai Renji Hospital
Learn More & Join Trial
HERO-UTUC: Intravesical RC48 After RNU for HER2+ UTUC PHASE2 This is a prospective, single-center, single-arm phase II study evaluating ...
Show More Location
Renji Hospital, School of Medicine, Shanghai Jiao Tong University
Learn More & Join Trial
Efficacy and Safety of Two Bladder-preserving Treatment Durations With Disitamab Vedotin Plus Toripalimab Combination in Her2-expressing Muscle-invasive Bladder Cancer: A Phase II, Open-Label, Randomized Clinical Trial PHASE2 This study aims to evaluate the efficacy of disitamab vedotin combined with...
Show More Location
Multiple Locations
Learn More & Join Trial
DV+BCG in HER2-Expressing, BCG-Naïve High-Risk NMIBC PHASE3 The purpose of this study is to learn about the safety and effects of the s...
Show More Location
Fudan University Shanghai Cancer Center
Learn More & Join Trial